The cystic Fibrosis Foundation issued the following clinical trial alerts in July.
July 6, 2022
SHIP CT: Study of hypertonic saline in preschoolers
Status: Completed with Results
Description: This study took place in Europe, Australia and the U.S. It evaluated the safety and effectiveness of hypertonic saline compared to isotonic saline (normal saline) in preschool children with CF.
Age: 3 Years to 5 Years
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 6
Length of Participation: 54 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02950883
Phase 2 study of CTX-4430 in people with CF (EMPIRE)
Status: Completed with Results
Description: This study evaluated the safety and effectiveness of the anti-inflammatory drug CTX-4430 (acebilustat)This study evaluated the safety and effectiveness of the anti-inflammatory drug CTX-4430 (acebilustat).
Age: 18 Years to 30 Years
Mutation: No Mutation Requirement
Fev1% Predicted: 50% or greater
Number of Visits: 15
Length of Participation: 1 years
ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT02443688
Study of ELX-02 in adults with cystic fibrosis who have at least one nonsense mutation
Status: Enrolling
Description: This study will look at the safety and tolerability of ELX-02 and how the body processes the drug, a molecule intended to restore CFTR function. Multiple doses of ELX-02 will be tested in adults with cystic fibrosis who have at least one G542X or similar nonsense mutation.
Age: 18 Years and Older
Mutation: No Copies F508del
Fev1% Predicted: 40% or greater
Number of Visits: 8
Length of Participation: 9 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04135495